Rep. James French Hill discloses trade(s) in KD, PFE, SFL, SOLV
James French Hill (AR02) disclosed 4 transactions, traded Dec 31: 0 purchases and 4 sales.
| Traded | Ticker | Company | Action | Amount | Owner |
|---|---|---|---|---|---|
| Dec 31 | KD | Kyndryl Holdings, Inc. | Sell | $1,001 - $15,000 | Self |
| Dec 31 | PFE | HILL 1998 TRUST Pfizer, Inc. | Sell | $100,001 - $250,000 | Self |
| Dec 31 | SFL | Sale of full position for tax loss purposes. SFL Corporation Ltd | Sell | $15,001 - $50,000 | Self |
| Dec 31 | SOLV | Sale of full position for tax loss purposes. Solventum Corporation | Sell | $15,001 - $50,000 | Self |
ORIGINAL FILING ↗ALL FILINGS BY JAMES FRENCH HILL →CONGRESS TRADES DASHBOARD →
Amounts are the ranges members report. Rows are read automatically from the filing; a trade split across a page break can be missed, so the original filing is the full record.
What This Means
A U.S. representative has filed a financial disclosure covering stock transactions in four companies spanning pharmaceuticals, shipping, and biotech. Congressional stock trading disclosures are public records that can signal insider positioning or serve as a transparency checkpoint for potential conflicts of interest. Markets monitor such filings for patterns that might indicate legislative intent or advance knowledge of policy shifts affecting those sectors.
Sources — 1 tier
Every claim below links directly to the original reporting it was drawn from. Penblock synthesizes and cross-references these sources — it doesn't originate the reporting.
- Hon. James French HillSep 29, 2026Rep. James French Hill discloses trade(s) in KD, PFE, SFL, SOLV ↗
How This Could Play Out — recorded when first flagged, not updated
Resolve
LIKELYThis disclosure represents routine tax-loss harvesting by a congressional member and would likely have no material market impact, as such filings are procedurally expected and reflect personal portfolio management rather than material non-public information.
Left Unattended
LIKELYIf no subsequent scrutiny or controversy emerges around the timing or rationale for these sales, the disclosure would fade from public attention with negligible effect on the underlying securities or broader market sentiment.
Escalate
UNLIKELYShould investigative reporting or regulatory review suggest the trades were timed to exploit material non-public information or violated the STOCK Act, reputational damage to the member could intensify broader congressional trading scrutiny, though direct price pressure on the four securities would remain minimal.
SPONSORED
Confidence History
- HIGH CONFIDENCESep 29, 2026 at 12:02 AM
Legally mandated financial disclosure filing -- primary source, not a report about the event